Ligand Pharmaceuticals (LGND) reported Q1 core adjusted net income Thursday of $1.33 per diluted share, up from $1.20 a year earlier.
Analysts polled by FactSet expected $1.21.
Revenue for the quarter ended March 31 was $45.3 million, up from $31 million a year earlier.
Analysts surveyed by FactSet expected $38.7 million.
The company said it continues to expect 2025 adjusted diluted EPS between $6.00 and $6.25 on revenue of $180 million to $200 million.
Analysts polled by FactSet expect full-year adjusted EPS of $6.11 and revenue of $190.9 million.
Shares were 0.9% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。